替罗非班单抗血小板治疗在破裂动脉瘤支架辅助栓塞或血流导向装置及脑室引流中的安全性与有效性
本研究回顾性评估了19例接受支架辅助栓塞或血流导向装置治疗的破裂动脉瘤性蛛网膜下腔出血患者,使用持续替罗非班输注(0.10 μg/kg/min,无负荷剂量)作为单抗血小板治疗,共涉及25例次脑室引流操作(19例EVD,6例VPS)。结果显示2例(8.3%)EVD后出现无症状轨道出血,1例腹膜后大出血,1例短暂性血小板减少,1例(4%)短暂性脑缺血发作。结论认为长期静脉替罗非班单药治疗在围手术期是安全的。
要点
- 替罗非班单抗血小板治疗用于aSAH支架/血流导向术后脑室引流患者,出血并发症率较低。
- EVD后无症状轨道出血发生率8.3%,无VPS相关出血。
- 短暂性脑缺血发作发生率4%,停药或补负荷后缓解。
核心结论
- 长期静脉替罗非班单药治疗在aSAH患者接受血管内支架辅助栓塞或血流导向装置治疗的围手术期是安全的。
研究设计与样本
- 回顾性安全性分析,纳入2017年7月至2018年9月期间接受SAC或FDD治疗的aSAH患者19例,均接受持续替罗非班输注(0.10 μg/kg/min,无负荷剂量)作为单抗血小板治疗。
主要发现
- 19例患者共接受25例次操作,包括19例EVD和6例VPS。
- 2例(8.3%)EVD置入后出现小的无症状轨道出血。
- 1例发生肾动脉分支损伤导致的大腹膜后出血,1例发生特发性短暂性血小板减少(停药后缓解)。
- 1例(4%)发生短暂性脑缺血发作,给予替罗非班负荷后缓解。
- 无VPS手术相关出血。
关键数值与推荐
- 替罗非班持续输注方案为0.10 μg/kg/min,无预先负荷剂量。
临床怎么用
- 对于接受SAC或FDD的aSAH患者,在需要EVD或VPS时,可考虑使用持续替罗非班单抗血小板治疗以平衡出血与缺血风险。
局限性
- 回顾性设计,样本量小(19例),无对照组,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemorrhagic complications are a major concern for aneurysmal subarachnoid hemorrhage patients treated with stenting or stent-assisted coiling and undergoing additional procedures such as shunting, ventriculostomy placement, and craniotomies/craniectomies. OBJECTIVE: To assess the safety and efficacy of using a continuous infusion of tirofiban as a monoantiplatelet therapy in the management of ruptured aneurysms in the setting of either stent-assisted coiling (SAC) or flow diversion devices (FDD) in patients requiring either an external ventricular drain (EVD) or ventriculoperitoneal shunt (VPS). METHODS: Aneurysmal subarachnoid hemorrhage (aSAH) patients between July 2017 and September 2018 who were treated with SAC or FDD were started on a continuous tirofiban infusion protocol (0.10 μg/kg/min) with no preceding loading dose as a monoantiplatelet therapy. Safety analysis was performed retrospectively to assess the complication rate, hemorrhagic rate, and rate of ischemic events. There were no hemorrhages related to the VPS surgery. RESULTS: Nineteen subjects were included in the series. The patients received a total of 25 procedures that included 19 EVDs and 6 VPSs. Two patients (8.3%) developed small asymptomatic track hemorrhages after EVD placement. One patient developed a large retroperitoneal hemorrhage due to renal artery branch injury during procedure, and another patient developed an idiosyncratic transient thrombocytopenia which resolved after stopping the medication. One patient (4%) developed a transient ischemic attack, which resolved after a bolus of tirofiban. CONCLUSION: Our study suggests that long-term use of intravenous tirofiban monotherapy in aSAH subjects for endovascular SAC or FDD is safe in the perioperative setting.
引用
- Limaye K, Zanaty M, Hudson J, et al. The Safety and Efficacy of Continuous Tirofiban as a Monoantiplatelet Therapy in the Management of Ruptured Aneurysms Treated Using Stent-Assisted Coiling or Flow Diversion and Requiring Ventricular Drainage. Neurosurgery. 2019. PMID: 31298301. doi:10.1093/neuros/nyz226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。